Literature DB >> 18351286

Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization.

Johan P Rung1, Emilia Rung, Lisa Helgeson, Anette M Johansson, Kjell Svensson, Arvid Carlsson, Maria L Carlsson.   

Abstract

Dopaminergic stabilizers can be defined as drugs that stimulate or inhibit dopaminergic signalling depending on the dopaminergic tone. (-)-OSU6162 and ACR16 appear to possess such a profile. They have been proposed to act as partial dopamine receptor agonists or as antagonists with preferential action on dopaminergic autoreceptors. Previous studies have shown either stimulation or inhibition of behaviour in response to (-)-OSU6162 and ACR16, which has been suggested to reflect their dual effects on dopaminergic signalling. The aims of the present work are to (1) examine the relation between behavioural response to these drugs and activity baseline, and (2) test the suggested mechanisms of action by means of close comparisons with the known partial D2-receptor agonists (-)-3-PPP and aripiprazole, and the D2 autoreceptor preferring antagonist amisulpride with respect to effects on behaviour. From the results of these experiments it can be concluded that: (1) The direction of the response to (-)-OSU6162 and ACR16 is dependent on activity baseline, which in turn, under physiological conditions, is determined primarily by test arena size of and degree of habituation to the environment. (2) The effects of (-)-OSU6162 and ACR16 cannot be explained on the basis of either partial dopamine receptor agonism or preferential dopamine autoreceptor antagonism. Nevertheless, the current data suggest at least two different D2-receptor-associated targets which mediate opposite effects on activity. This result fits in with a mechanism proposed from a recent in vitro study, according to which (-)-OSU6162 has a dual action on dopamine D2 receptors, (a) an allosteric effect causing an enhanced response to dopamine, and (b) the previously proposed orthosteric effect antagonizing the action of dopamine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18351286     DOI: 10.1007/s00702-008-0038-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

1.  A half-century of neurotransmitter research: impact on neurology and psychiatry (Nobel lecture).

Authors:  A Carlsson
Journal:  Chembiochem       Date:  2001-08-03       Impact factor: 3.164

2.  The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys.

Authors:  M Brandt-Christensen; M B Andersen; A Fink-Jensen; T Werge; J Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2005-03-30       Impact factor: 3.575

3.  Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease.

Authors:  J Tedroff; A Ekesbo; C Sonesson; N Waters; A Carlsson
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

4.  Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.

Authors:  G Perrault; R Depoortere; E Morel; D J Sanger; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

5.  Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis.

Authors:  Philip Seeman; Hong-Chang Guan
Journal:  Eur J Pharmacol       Date:  2006-11-14       Impact factor: 4.432

6.  The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats.

Authors:  Johan P Rung; Arvid Carlsson; Katarina Rydén Markinhuhta; Maria L Carlsson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-06       Impact factor: 5.067

7.  In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.

Authors:  Shaun Jordan; Karen Regardie; Janelle L Johnson; Ruoyan Chen; Junichi Kambayashi; Robert McQuade; Hisashi Kitagawa; Yoshihiro Tadori; Tetsuro Kikuchi
Journal:  J Psychopharmacol       Date:  2006-11-08       Impact factor: 4.153

8.  Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.

Authors:  Shaun Jordan; Janelle L Johnson; Karen Regardie; Ruoyan Chen; Vuk Koprivica; Yoshihiro Tadori; Junichi Kambayashi; Hisashi Kitagawa; Tetsuro Kikuchi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-10-27       Impact factor: 5.067

9.  Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour.

Authors:  N Waters; L Löfberg; S Haadsma-Svensson; K Svensson; C Sonesson; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 10.  Schizophrenia: from dopamine to glutamate and back.

Authors:  M L Carlsson; A Carlsson; M Nilsson
Journal:  Curr Med Chem       Date:  2004-02       Impact factor: 4.530

View more
  24 in total

1.  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.

Authors:  Daniel Ryskamp; Jun Wu; Michal Geva; Rebecca Kusko; Iris Grossman; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2016-11-03       Impact factor: 5.996

2.  The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans.

Authors:  A Helldén; G Panagiotidis; P Johansson; N Waters; S Waters; J Tedroff; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2012-03-08       Impact factor: 2.953

3.  II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.

Authors:  Ethan S Burstein; Maria L Carlsson; Michelle Owens; Jian-Nong Ma; Hans H Schiffer; Arvid Carlsson; Uli Hacksell
Journal:  J Neural Transm (Vienna)       Date:  2011-08-25       Impact factor: 3.575

4.  The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.

Authors:  Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

5.  Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.

Authors:  Johan P Rung; Emilia Rung; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

6.  I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.

Authors:  Maria L Carlsson; Ethan S Burstein; Angélica Kloberg; Sarah Hansson; Arja Schedwin; Marie Nilsson; Johan P Rung; Arvid Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2011-08-28       Impact factor: 3.575

7.  Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.

Authors:  Benjamin Ray Miller; Ilya Bezprozvanny
Journal:  Future Neurol       Date:  2010-09

8.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

9.  Caffeine's Attenuation of Cocaine-Induced Dopamine Release by Inhibition of Adenosine.

Authors:  Lauren B Malave; Patricia A Broderick
Journal:  J Caffeine Res       Date:  2014-06-01

10.  The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.

Authors:  Nelleke Tolboom; Henk W Berendse; Josee E Leysen; Maqsood Yaqub; Bart N M van Berckel; Robert C Schuit; Mirthe M Ponsen; Esther Bakker; Nikie J Hoetjes; Albert D Windhorst; Maria L Carlsson; Adriaan A Lammertsma; Arvid Carlsson
Journal:  Neuropsychopharmacology       Date:  2014-08-05       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.